John Paulson's investment portfolio showcases a strategic inclination towards pharmaceuticals and resource-based companies. Madrigal Pharmaceuticals Inc, a leader in developing innovative therapies for cardiovascular-metabolic diseases, holds a significant position in Paulson's stocks collection, testifying to his faith in biotech's growth potential. Bausch Health Companies Inc further diversifies his interest in the healthcare sector, with this company being a global provider of diversified pharmaceuticals.
The finance sector is represented through BrightSphere Investment Group Inc, where Paulson sees value in asset management firms. This aligns with a broader investment play on financial services industry dynamics.
Heading into natural resources, Perpetua Resources Corp reflects Paulson's bet on sustainable mining operations, indicating an environmentally conscious yet profitability-focused strategy. Novagold Resources Inc complements this approach with its stake in precious metal exploration—particularly gold—which acts as a hedge against market volatility and inflation.
Paulson's top five investments reveal a balanced mix between high-growth potential pharma and steady-eddy resource sectors, signaling a blended risk appetite to seasoned and novice investors alike.
Central bank gold buying and global trade tensions are likely to push bullion prices to near $5,000 an ounce by 2028, billionaire investor John Paulson said in an interview duri...
Upping his exposure to one of the hottest investments this year, billionaire investor John Paulson is teaming up with Canada's NovaGold Resources Inc. to purchase a stake in an ...
Paulson Advisers will acquire a 40% ownership interest in Donlin Gold NOVAGOLD will increase its ownership interest in Donlin Gold from 50% to 60% Donlin Gold to be managed join...
John Paulson's dividend stocks (May 2025) include Agnico Eagle Mines (AEM), a gold mining company focused on gold reserve development.
John Paulson's top April 2025 holding is Madrigal Pharmaceuticals (MDGL), focused on NASH therapies.